Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes

BackgroundAtrial fibrillation is a common complication of acute myocardial infarction with an incidence varying from 5% to 20%. New-onset atrial fibrillation developing after acute myocardial fibrillation indicates a significantly increased risk of death and stroke. Diabetes mellitus, as a shared ri...

Full description

Bibliographic Details
Main Author: ZHENG Rujie, WANG Yue, JIANG Yaohui, ZHANG Jinying
Format: Article
Language:zho
Published: Chinese General Practice Publishing House Co., Ltd 2022-02-01
Series:Zhongguo quanke yixue
Subjects:
Online Access:https://www.chinagp.net/fileup/1007-9572/PDF/1643428285535-1056172870.pdf
_version_ 1797217218893709312
author ZHENG Rujie, WANG Yue, JIANG Yaohui, ZHANG Jinying
author_facet ZHENG Rujie, WANG Yue, JIANG Yaohui, ZHANG Jinying
author_sort ZHENG Rujie, WANG Yue, JIANG Yaohui, ZHANG Jinying
collection DOAJ
description BackgroundAtrial fibrillation is a common complication of acute myocardial infarction with an incidence varying from 5% to 20%. New-onset atrial fibrillation developing after acute myocardial fibrillation indicates a significantly increased risk of death and stroke. Diabetes mellitus, as a shared risk factor in both acute myocardial infarction and atrial fibrillation, plays an important role in the development of acute myocardial infarction and atrial fibrillation. It has been reported that dapagliflozin, a new hypoglycemic agent, has a positive effect on lowering glucose. However, there are few data regarding its impact on the risk of atrial fibrillation after acute myocardial infarction in patients with diabetes.ObjectiveTo investigate the effect of dapagliflozin on the risk of new-onset atrial fibrillation after acute myocardial infarction in patients with type 2 diabetes mellitus.MethodsTotal 764 patients with type 2 diabetes mellitus admitted during December 2018 to June 2020 in Cardiovascular Department, the First Affiliated Hospital of Zhengzhou University for acute myocardial infarction were selected. The demographic data, echocardiographic indices and laboratory data were collected, and compared between participants with new-onset atrial fibrillation (n=188) and those without (n=576) . Multivariate Logistic regression analysis was used to assess the impact of dapagliflozin on the risk of new-onset atrial fibrillation after acute myocardial infarction.ResultsPatients with new-onset atrial fibrillationhad older mean age, higher male proportion, and proportion of smokers, higher mean levels of glycosylated hemoglobin, left atrial diameter, NT-proBNP and C-reactive protein, and lower mean levels of systolic blood pressure and high-density lipoprotein, as well as lower prevalence of using insulinand dapagliflozinthan those without (P<0.05) . Multivariate Logistic regression analysis found that dapagliflozin was associated with a 34% reduced risk for new-onset atrial fibrillation after acute myocardial infarction in patients with type 2 diabetes mellitus 〔OR=0.66, 95%CI (0.57, 0.91) , P=0.008〕.ConclusionDapagliflozin may be associated with a lower risk of new-onset atrial fibrillation after acute myocardial infarction in type 2 diabetics.
first_indexed 2024-04-24T11:58:22Z
format Article
id doaj.art-253fb82fdde04e60b550d6831cf23322
institution Directory Open Access Journal
issn 1007-9572
language zho
last_indexed 2024-04-24T11:58:22Z
publishDate 2022-02-01
publisher Chinese General Practice Publishing House Co., Ltd
record_format Article
series Zhongguo quanke yixue
spelling doaj.art-253fb82fdde04e60b550d6831cf233222024-04-09T02:50:52ZzhoChinese General Practice Publishing House Co., LtdZhongguo quanke yixue1007-95722022-02-01250554254610.12114/j.issn.1007-9572.2021.01.024Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 DiabetesZHENG Rujie, WANG Yue, JIANG Yaohui, ZHANG Jinying0 Cardiovascular Department,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China *Corresponding author:ZHANG Jinying,Chief physician;E-mail:jyzhang@zzu.edu.cn BackgroundAtrial fibrillation is a common complication of acute myocardial infarction with an incidence varying from 5% to 20%. New-onset atrial fibrillation developing after acute myocardial fibrillation indicates a significantly increased risk of death and stroke. Diabetes mellitus, as a shared risk factor in both acute myocardial infarction and atrial fibrillation, plays an important role in the development of acute myocardial infarction and atrial fibrillation. It has been reported that dapagliflozin, a new hypoglycemic agent, has a positive effect on lowering glucose. However, there are few data regarding its impact on the risk of atrial fibrillation after acute myocardial infarction in patients with diabetes.ObjectiveTo investigate the effect of dapagliflozin on the risk of new-onset atrial fibrillation after acute myocardial infarction in patients with type 2 diabetes mellitus.MethodsTotal 764 patients with type 2 diabetes mellitus admitted during December 2018 to June 2020 in Cardiovascular Department, the First Affiliated Hospital of Zhengzhou University for acute myocardial infarction were selected. The demographic data, echocardiographic indices and laboratory data were collected, and compared between participants with new-onset atrial fibrillation (n=188) and those without (n=576) . Multivariate Logistic regression analysis was used to assess the impact of dapagliflozin on the risk of new-onset atrial fibrillation after acute myocardial infarction.ResultsPatients with new-onset atrial fibrillationhad older mean age, higher male proportion, and proportion of smokers, higher mean levels of glycosylated hemoglobin, left atrial diameter, NT-proBNP and C-reactive protein, and lower mean levels of systolic blood pressure and high-density lipoprotein, as well as lower prevalence of using insulinand dapagliflozinthan those without (P<0.05) . Multivariate Logistic regression analysis found that dapagliflozin was associated with a 34% reduced risk for new-onset atrial fibrillation after acute myocardial infarction in patients with type 2 diabetes mellitus 〔OR=0.66, 95%CI (0.57, 0.91) , P=0.008〕.ConclusionDapagliflozin may be associated with a lower risk of new-onset atrial fibrillation after acute myocardial infarction in type 2 diabetics.https://www.chinagp.net/fileup/1007-9572/PDF/1643428285535-1056172870.pdf|diabetes mellitus, type 2|dapagliflozin|myocardial infarction|atrial fibrillation|hospitalization|risk reduction behavior|root cause analysis
spellingShingle ZHENG Rujie, WANG Yue, JIANG Yaohui, ZHANG Jinying
Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes
Zhongguo quanke yixue
|diabetes mellitus, type 2|dapagliflozin|myocardial infarction|atrial fibrillation|hospitalization|risk reduction behavior|root cause analysis
title Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes
title_full Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes
title_fullStr Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes
title_full_unstemmed Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes
title_short Effect of Dapagliflozin on the Risk of New-onset Atrial Fibrillation during Hospitalization for Acute Myocardial Infarction in Patients with Type 2 Diabetes
title_sort effect of dapagliflozin on the risk of new onset atrial fibrillation during hospitalization for acute myocardial infarction in patients with type 2 diabetes
topic |diabetes mellitus, type 2|dapagliflozin|myocardial infarction|atrial fibrillation|hospitalization|risk reduction behavior|root cause analysis
url https://www.chinagp.net/fileup/1007-9572/PDF/1643428285535-1056172870.pdf
work_keys_str_mv AT zhengrujiewangyuejiangyaohuizhangjinying effectofdapagliflozinontheriskofnewonsetatrialfibrillationduringhospitalizationforacutemyocardialinfarctioninpatientswithtype2diabetes